Form 4: Cyclo Therapeutics Director Toig Receives Stock and Options as Compensation

Randall M. Toig, a director of Cyclo Therapeutics, Inc., acquired shares and options as part of his compensation, according to a recent SEC filing.

Summary

• On June 3, 2024, Randall M. Toig, a director of Cyclo Therapeutics, Inc., acquired 10,352 shares of common stock.
• These shares were granted in lieu of cash compensation for the first quarter of 2024, as per the company's non-employee director compensation policy.
• The shares were valued at $1.28 each, based on the closing price on June 3, 2024.
• Toig also acquired options to purchase 15,562 shares of common stock at an exercise price of $1.28 per share.
• The options vest over a one-year period in equal quarterly installments and expire on June 3, 2034.
• Following these transactions, Toig directly owns 115,243 shares of Cyclo Therapeutics common stock and options for 15,562 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director accepting stock in lieu of cash is a good sign, but it's a routine transaction.

Positives

• The director's acceptance of stock in lieu of cash compensation demonstrates confidence in the company's future.
• The vesting schedule of the options aligns the director's interests with the long-term performance of the company.

Industry Context

Director compensation packages often include a mix of cash and equity to align management's interests with those of shareholders. Granting stock and options is a common practice.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning their interests with shareholders.
• The dilution effect of the new shares is minimal.

Key Dates